Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending September 29, 2008. The report details a specific corporate action regarding the repurchase and cancellation of the company's ordinary shares, executed under authority granted by shareholders at the Annual General Meeting on May 21, 2008.
Key Financial Metrics
The filing does not provide comprehensive financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. It focuses exclusively on share repurchase activity.
- Shares Purchased: 850,000 ordinary shares of 25 pence each.
- Purchase Date: September 29, 2008.
- Purchase Price: 1,199.33 pence per share.
- Treasury Shares Held: 474,194,158 shares (representing 9.09% of total voting rights).
- Shares in Issue: 5,217,945,776 shares (excluding Treasury shares).
Material Changes
The primary material change reported is the reduction of the company's share capital through the cancellation of 850,000 repurchased shares. Consequently, the number of shares held in Treasury increased to 474,194,158. The filing does not provide comparative data against prior periods for financial performance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, or outlook for future periods. It includes a standard disclaimer stating that the announcement does not constitute an offer or solicitation to purchase securities and is made in conformity with the Financial Services Authority's Disclosure and Transparency Rules.
Investor Verification Checklist
- Verify the total number of shares in issue (5,217,945,776) for calculating disclosure thresholds under FSA rules.
- Confirm the updated Treasury share count (474,194,158) and its percentage of total voting rights (9.09%).
- Note that this filing does not contain quarterly or annual financial results; refer to Form 20-F for comprehensive financial data.